fluvoxamine and ferric-nitrilotriacetate

The effects of oxidative stress (OS) on the pharmacokinetics of fluvoxamine (FLV), particularly on FLV distribution in the plasma, were studied in ferric-nitrilotriacetate-induced OS rat models (OS rats). The study protocol involved a continuous FLV infusion (25.0 μg/kg/min). The resulting mean plasma FLV concentration measured in steady state OS rats was 0.13 ± 0.01 μg/mL, which was significantly lower than plasma concentrations measured in control rats (0.19 ± 0.01 μg/mL). Moreover, the mean FLV concentration in the OS rat brain (0.51 ± 0.08 μg/g) was determined to be approximately half the concentration in control rat brains (0.95 ± 0.11 μg/g). The FLV concentrations in both the unbound fraction of plasma and erythrocytes of OS rats were significantly greater than that of control rats. These results suggest the potential attenuation of FLV's pharmacological effects in patients under OS.

Topics: Animals; Biological Availability; Blood Proteins; Blood-Brain Barrier; Brain; Ferric Compounds; Fluvoxamine; Humans; Injections, Intravenous; Male; Nitrilotriacetic Acid; Oxidative Stress; Protein Binding; Rats; Rats, Wistar; Reactive Oxygen Species; Selective Serotonin Reuptake Inhibitors; Thiobarbituric Acid Reactive Substances